Adverum Biotechnologies Initiated at Outperform by Oppenheimer

Adverum Biotechnologies Initiated at Outperform by Oppenheimer

Dow JonesJun 25 20:41

Oppenheimer Initiates Adverum Biotechnologies(ADVM.US) With Buy Rating, Announces Target Price $25

Oppenheimer analyst Francois Brisebois initiates coverage on $Adverum Biotechnologies(ADVM.US)$ with a buy rating, and sets the target price at $25.According to TipRanks data, the analyst has a succes

Futu NewsJun 25 20:33 · Ratings

Express News | Adverum Biotechnologies Inc : Oppenheimer Initiates Coverage With Outperform Rating; Target Price $25

BreakingsJun 25 20:18

Adverum Biotechnologies to Participate in TD Cowen's Genetic Medicines & RNA Summit

REDWOOD CITY, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly

GlobeNewswireJun 18 20:00

Express News | Adverum Biotechnologies Announces Appointments of DR. Rabia Gurses Ozden as Chief Medical Officer and DR. Szilárd Kiss as a Member of the Board of Directors

BreakingsJun 11 20:00

Strong Buy Rating for Adverum Biotechnologies Amid Anticipated Positive Phase 2 Results and Market Undervaluation

TipRanksMay 16 16:39